David B. Klein is a healthcare innovator and entrepreneur with more than 20 years of experience in the life science industry and a passion for developing novel patient-centric treatments. In 2012, recognizing the impact of smartphones on cognition, he began a journey to leverage software to improve clinical outcomes. He created the term Digital Therapeutics™ and founded Click Therapeutics, which develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs.
In collaboration with Otsuka, Click Therapeutics developed Rejoyn™, the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms. In addition, the company discovered and developed CT-132, the first ever prescription digital therapeutic authorized by the FDA for the preventive treatment of episodic migraine. Click has digital therapeutics under development in a wide variety of therapeutic areas including psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
David is a staunch advocate for rigorous development and high-quality evidence standards. His mission is to create safer, more efficacious treatments by combining software and drugs, believing collaborations between tech and pharma will revolutionize the standard of care and improve access to high-quality medical treatments globally.